News | May 13, 2021
Torrent Pharma enters into agreement with Lilly for Baricitinib for Covid-19 in India
The agreement will help ensure wider reach and access to patients in India
The agreement will help ensure wider reach and access to patients in India
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
Alembic has reported total income of Rs.83.79 crores during the FY ended March 31, 2021
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in-their respective categories as on March 2021.
Subscribe To Our Newsletter & Stay Updated
